The aims of this study were 1) to investigate the mRNA pattern of CD44 variants in three primary (MIA PaCa 2, PANC-1, PSN-1) and two metastatic (CAPAN-1, SUIT-2) pancreatic cancer (PC) cell lines; 2) to ascertain whether the genetic transfer of CD44s and CD44v10 modifies the adhesion of PC cells to the extracellular matrix (ECM) in vitro and their metastatic behavior in vivo.
Methods
CD44 mRNA analysis was done by means of RT-PCR. Adhesion to ECM the was assessed using coated microtiter plates. For the study of CD44v10 insertion in the CAPAN-1 line, liposome-mediated DNA transfer was used. SCID mice were employed for in vivo experiments.
Results
CD44v10 mRNA was not expressed by the CAPAN-1 nor by four of the six SUIT-2-derived clones. The stable expression of CD44v10 by modified CAPAN-1 significantly enhanced fibronectin adhesion. Mice without either liver or pancreatic metastases were more frequently found among the animals injected with modified (CD44v10 expressing) than with non-modified CAPAN-1.
Conclusions
1) It is possible to differentiate between metastatic and non-metastatic PC cells on the basis of CD44v10 expression; 2) CD44v10 seems to be involved in mediating fibronectin adhesion in vitro and in counteracting metastases in vivo.
CoopermanA.M.Pancreatic cancer: the bigger picture. Surg Clin North Am2001; 81: 557–74.
2.
LiottaL.A., StevensonW.G.S.Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res1991; 51: 5054s–9s.
3.
JiangW.G., PuntisM.C.A., HallettM.B.Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg1994; 81: 1576–90.
4.
RosewiczS., WollbergsK., Von LampeB., MatthesH., KaiserA., RieckenE.O.Retinoids inhibit adhesion to laminin in human pancreatic carcinoma cells via the α6β1-integrin receptor. Gastroenterology1997; 112: 532–42.
5.
SaikiI.Cell adhesion molecules and cancer metastasis. Jpn J Pharmacol1997; 75: 215–42.
6.
SilversteinJ.J., SilversteinR.L.Cell adhesion molecules: an overview. Cancer Invest1998; 16: 176–82.
StallmachA., Von LampeB., OrzechowskiH.D., MatthesH., RieckenE.O.Increased fibronectin-receptor expression in colon carcinoma-derived HT29 cells decreased tumorigenicity in nude mice. Gastroenterology1994; 106: 19–27.
14.
TakadaM., YamamotoM., SaitohY.The significance of CD44 in human pancreatic cancer (II): the role of CD44 in human pancreatic adenocarcinoma invasion. Pancreas1994; 9: 753–7.
15.
GunjiN., OdaT., TodorakiT.. Pancreatic carcinoma: correlation between E-cadherin and α-catenin expression status and liver metastasis. Cancer1998; 82: 1649–56.
16.
SneathR.J.S., ManghamD.C.The normal structure and function of CD44 and its role in neoplasia. Mol Pathol1998; 51: 191–200.
17.
Weg-RemersS., AndersM., Von LampeB.. Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. Eur J Cancer1998; 34: 1607–11.
18.
EndoK., TeradaT.Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol2000; 32: 78–84.
19.
ImamH., ErikssonB., ObergK.Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours. Ann Oncol2000; 11: 295–300.
20.
RingelJ., JesnowskiR., SchmidtC.. CD44 in normal human pancreas and pancreatic carcinoma cell lines. Teratog Carcinog Mutagen2001; 21: 97–106.
21.
VogelmannR., KreuserE.D., AdlerG., LutzM.P.Integrin α6β1 role in metastatic behavior of human pancreatic carcinoma cells. Int J Cancer1999; 80: 791–5.
22.
IshidaT.Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma. Jpn J Surg2000; 30: 28–32.
23.
MiyakeH., OkamotoI., HaraI.. Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8-10/CD44v10 competitive RT-PCR. Int J Cancer1998; 79: 560–4.
24.
LiN., TsujiM., KandaK., MurakamiY., KanayamaH., KagawaS.Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU Int2000; 85: 514–8.
25.
StefaniA.L., BassoD., PanozzoM.P.. Cytokines modulate MIA PaCa 2 and CAPAN-1 adhesion to extracellular matrix proteins. Pancreas1999; 19: 362–9.
26.
IwamuraT., CaffreyT.C., KitamuraN., YamanariH., SetoguchiT., HollingsworthM.A.P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Res1997; 57: 1206–12.
27.
AlbiniA., IwamotoY., KleinmanH.K.. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res1987; 47: 3239–45.
28.
GotodaT., MatsumuraY., KondoH.. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res1998; 89: 1033–40.
29.
PereiraP.A., RubenthiranU., KanekoM., JothyS., SmithA.J.CD44s expression mitigates the phenotype of human colorectal cancer hepatic metastases. Anticancer Res2001; 21: 2713–7.
30.
AsosinghK., GunthertU., De RaeveH., Van RietI., Van CampB., VanderkerkenK.A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res2001; 61: 2862–5.
31.
WeimannT.K., WagnerC., FunkR., HircheH., GoosM., WagnerS.N.Hyaluronan-independent adhesion of CD44H+ and CD44v10+ lymphocytes to dermal microvascular endothelial cells and keratinocytes. J Invest Dermatol2001; 117: 949–57.
32.
RoselM., KhaldoyanidiS., ZawadzkiV., ZollerM.Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol1999; 27: 698–711.
